Dalnacogene ponparvovec in Hemophilia B: NCT05709288 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
not reported
Planned enrollment
2035-06-01
Primary-completion proxy
Executive view
NCT05709288 evaluates Dalnacogene ponparvovec in Hemophilia B. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is The incidence of treatment related adverse events deemed related to BBM-H901 within 10 weeks after vector administration, assessed over infusion to 10 weeks after vector infusion..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT05709288 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hemophilia B landscape. Drug & Asset MCP drug_fetch was queried for Dalnacogene ponparvovec, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT05709288 | Dalnacogene ponparvovec | Phase 1 / Recruiting | Sponsor not reported | China | The incidence of treatment related adverse events deemed related to BBM-H901 within 10 weeks after vector administration infusion to 10 weeks after vector infusion. | 2035-06-01 |
| NCT05789524 | Mutated alpha-1 antitrypsi(ApcinteX) | Phase 2 / Terminated | ApcinteX Ltd. | United States, United Kingdom, Spain, India, Armenia, Canada, Turkey, Belgium, Taiwan Province, Poland, South Africa, Italy, France, Australia, Germany | Annualized Bleeding Rate (ABR) for Treated Bleeds up to Week 24 Up to Week 24 | 2024-11-14 |
| NCT05707351 | Rurioctocog alfa pegol | Phase 3 / Completed | Takeda Pharmaceutical Co., Ltd. | China | Total Annualized Bleeding Rates (ABR) Baseline through study completion or ≥50 EDs whichever occurred last… | 2024-09-05 |
| NCT05695391 | Coagulation factor VIIa (recombinant)-jncw(LFB Biotechnologies SASU) | Phase 3 / Terminated | Laboratoire Français du Fractionnement et des Biotechnologies | United States, Turkey, South Africa, Mexico, Malaysia, Thailand | Eptacog Beta (Activated) (EB) Effectiveness Based on Protocol's Aggregate Score From surgical wound closure until 120 hours after surgical wound clos… | 2025-05-28 |
| NCT05685238 | Denecimig | Phase 3 / Active, not recruiting | Novo Nordisk A/S | United States, Malaysia, Portugal, Saudi Arabia, South Korea, Netherlands, Latvia, Austria, Ireland, China, Turkey, Poland, Slovakia, Serbia, Lithuania, France, Bulgaria, Romania, Japan, United Kingdom, Switzerland, Spain, India, Canada, Belgium, Taiwan Province, Denmark, South Africa, Mexico, Italy, Israel, Germany | Arm 1 and 2: Number of treatment emergent adverse events From week 0 until end of study (up to 283 weeks) | 2028-06-30 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT05709288 is a Phase 1, recruiting study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “The incidence of treatment related adverse events deemed related to BBM-H901 within 10 weeks after vector administration” over “infusion to 10 weeks after vector infusion..” The retrieved endpoint description is: the type and incidence of TRAE after BBM-H901 infusion according to the CTCAE(v5.0).
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Hemophilia B. These records do not establish direct evidence for NCT05709288 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Dalnacogene ponparvovec is indexed as AAV based gene therapy with factor IX biology and a global stage of Approved. The asset profile lists Belief BioMed, Inc. as an originator or developer.
No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Dalnacogene ponparvovec is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT05709288
Protocol source: https://clinicaltrials.gov/study/NCT05709288
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
Dalnacogene ponparvovec in Hemophilia B is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes The incidence of treatment related adverse events deemed related to BBM-H901 within 10 weeks after vector administration and 2035-06-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
